Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment (HyBraFi)
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Prostate cancer, brachytherapy, hypofractionated radiation therapy, hormonal therapy
Eligibility Criteria
Inclusion Criteria:
- 30 patients
- intermediate / extensive low risk (all core biopsies involvements > 50%)
- prostate cancer (not necessitating to treat the nodal regions)
- Patient stage T1 - T2,
- Gleason score ≤ 7,
- PSA ≤ 20 will be considered
Exclusion Criteria:
- patient unfit for biopsy or brachytherapy
- high or low risk prostate cancer
Sites / Locations
- CHUdeQuebec
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Hypofraction
Standard
Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists.